EU drafts industrial policy to reshore pharmaceuticals, deepening neoliberal supply chain fragility while ignoring systemic dependency on global capital
Original framing: “STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages” — STAT News
Future scenarios suggest that reshoring pharmaceutical production without addressing patent regimes and financialization will not resolve shortages but may exacerbate them by increasing costs and reducing flexibility. A systemic approach would involve diversifying supply chains, investing in public health infrastructure, and prioritizing community-based production models. The EU’s deal risks locking in a model that is vulnerable to future shocks, such as pandemics or climate disasters, by ignoring these long-term implications.
The EU’s draft deal to 'reshore' pharmaceutical production is a classic example of neoliberal industrial policy, where the symptoms of a crisis (shortages) are addressed without tackling its root causes (austerity, patent monopolies, financialization).
This approach deepens structural dependencies while obscuring the transnational nature of capital and labor, as well as the resilience of traditional medicine systems. The deal’s focus on 'local' production ignores the historical legacies of colonialism and the environmental costs of industrial manufacturing, instead reinforcing corporate control over health. A systemic solution would require decolonizing supply chains, reinvesting in public health, and regulating financial capital—moves that challenge the power of Big Pharma and EU elites. The trickster’s insight reveals the absurdity of treating medicines as commodities to be 'reshored' while ignoring the structural violence that created the shortages in the first place. Only by centering marginalized voices, historical patterns, and future resilience can the EU move beyond the hollow promises of industrial policy.